BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10365741)

  • 1. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
    Mustjoki S; Alitalo R; Stephens RW; Vaheri A
    Thromb Haemost; 1999 May; 81(5):705-10. PubMed ID: 10365741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
    Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J
    Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.
    Nadir Y; Katz T; Sarig G; Hoffman R; Oliven A; Rowe JM; Brenner B
    Haematologica; 2005 Nov; 90(11):1549-56. PubMed ID: 16266903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue factor (TF) and urokinase plasminogen activator receptor (uPAR) and bleeding complications in leukemic patients.
    López-Pedrera C; Jardí M; del Mar Malagón M; Inglés-Esteve J; Dorado G; Torres A; Félez J; Velasco F
    Thromb Haemost; 1997 Jan; 77(1):62-70. PubMed ID: 9031451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
    J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
    Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
    Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
    Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
    Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
    Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
    Song SJ; Hu JB; Wang HX; Wen SQ; Ding MP; Huang JZ
    Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1583-5. PubMed ID: 14642114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
    Cinque P; Nebuloni M; Santovito ML; Price RW; Gisslen M; Hagberg L; Bestetti A; Vago G; Lazzarin A; Blasi F; Sidenius N
    Ann Neurol; 2004 May; 55(5):687-94. PubMed ID: 15122709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
    Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P
    J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
    Henic E; Borgfeldt C; Christensen IJ; Casslén B; Høyer-Hansen G
    Clin Cancer Res; 2008 Sep; 14(18):5785-93. PubMed ID: 18794088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells.
    Ostrowski SR; Plomgaard P; Fischer CP; Steensberg AS; Møller K; Høyer-Hansen G; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Feb; 61(2):197-206. PubMed ID: 15683457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
    Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K
    Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
    Jumper C; Cobos E; Lox C
    Anticancer Res; 2002; 22(4):2073-6. PubMed ID: 12174885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.